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ABSTRACT
Objective: Angiogenesis the formation of new blood vessels from the pre-existing vasculature plays a major role in tumor growth, invasion, and 
metastasis of cancer diseases. The current research was designed for the inhibition of angiogenesis, which can provide a novel way to inhibit tumor 
growth and metastasis in cancer.
Methods: The antiangiogenic properties of serial concentrations of the hydroethanolic extract of Artocarpus heterophyllus were examined in human 
umbilical vein endothelial cells (HUVECs) using a tube formation assay in vitro and in a Matrigel plug assay as in vivo model.
Results: Hydroethanolic extract of A. heterophyllus significantly inhibited vascular endothelial growth factor (VEGF)-mediated angiogenesis in the 
HUVECs in culture dose-dependently. Further, the new blood vessel formation was observed to be inhibited by the extract at 100 mg/kg p.o. in Matrigel 
plug model in C57BL/6 mice. However, the effect was enhanced in higher concentration (500 mg/kg p.o.) demonstrating the in vivo antiangiogenic 
activity of the extract.
Conclusion: This study demonstrated that the hydroethanolic seed extract of A. heterophyllus strongly inhibited the angiogenesis in HUVECs. 
Moreover, the extract significantly inhibited the VEGF production in HUVECs, confirming their possible antiangiogenic mechanism.
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INTRODUCTION
Angiogenesis is the development of new blood vessels from pre-
existing blood vessels. It is host-dependent and is a hallmark of 
cancer that has an early permissive role in tumorigenesis [1]. The 
process of neovascularization not only allows the continued growth 
of the primary tumor but also provides migrating tumor cell access 
to the systemic circulation thereby facilitating metastasis [2]. In 
recent years, the involvement of angiogenesis in the development 
of malignant tumors and metastasis has been extensively studied. 
Therapeutic strategies to suppress angiogenesis have been examined 
on experimental tumor models with successful outcomes. Most cancer 
chemopreventive drugs, function by preventing angiogenesis in the 
tumor microenvironment by blocking vascularization [3]. Molecules 
possessing antiangiogenic effect hold great potential for treating diseases. 
During normal physiological conditions, the balance between angiogenic 
and antiangiogenic factors is essential for regulating angiogenesis [4]. 
Vascular endothelial growth factor (VEGF) and its tyrosine kinase VEGF 
receptors (VEGFRs) are the key regulators in angiogenesis and are highly 
conserved across vertebrate species [5]. Among them, VEGF-A, the most 
important member of the VEGF family, binds and activates the VEGFR2, 
and subsequently, activates the main signaling pathway [6]. This process 
of analyzing angiogenesis is studied using both in vitro and in vivo models 
using endothelial cell lines derived from human umbilical cord vein, or 
organ-specific endothelial cells have been used [7].
Medicinal plants represent a vast potential source for anticancer 
compounds by preventing angiogenesis. These plant-derived bioactive 
compounds for anticipation, mitigation, and therapeutics for cancer 
have been applied extensively which are otherwise extremely complex 
molecular structures, which would be difficult to synthesize (or 
conceptualize) in the laboratory. The antitumor activity of medicinal 
plant-derived compounds may result through a number of mechanisms, 
including effects on cytoskeletal proteins which play a key role in cell 
division, inhibition of DNA topoisomerase enzymes, antiprotease or 
antioxidant activity, and stimulation of the immune system. [8]. The 
natural compounds isolated from medicinal plants or parts of plants 
consumed in the form of food are believed to be major leads in the 
designing of anticancer medications. Screening of such medicinal 
plants and their bioactive constituents for several biological activities, 
such as anticancer activity, has been a key research area since last few 
decades [9]. Among which, many parts of plants have also provoked 
potential antiangiogenic activity. One such plant is Artocarpus 
heterophyllus which has been proved for its antioxidant and anticancer 
studies and not proved for its antiangiogenic property, so the current 
research focused on antiangiogenic property of the seed extract.
A. heterophyllus Lam, the plant used in the present investigation 
(Family; Moraceae) is of great interest, which is commonly known as 
jackfruit and is widely distributed in the tropical and temperate regions 
of the world. Secondary metabolites, including alkaloids, saponins, 
flavonoids, and phenolic content, were determined in the jackfruit 
seeds. The seeds are also a rich source of carbohydrates and proteins 
and a good source of fiber and vitamins [10]. The jackfruit seeds are 
consumed, usually as roasted, boiled, or steamed as a snack. Based on 
the minimum reports available, the present study is aimed to assess 
the antiangiogenic potential of the hydroethanolic extract of tegmen of 
A. heterophyllus seeds.
METHODS
Plant materials and extraction
A. heterophyllus seeds were obtained from Market, Trivandrum, 
Kerala. The inner thin membranous brown tegmen (Spermoderm) of 
A. heterophyllus seeds was used for the present study. The plant was 
identified and authenticated at Botanical Survey of India, Coimbatore 
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(No: BSI/SRC/5/23/2018/Tech-383). About 25g of the inner thin 
membranous brown tegmen of the jackfruit seed was dried and 
powdered. The powdered material of A. heterophyllus seeds was 
extracted with hydro-ethanol using Soxhlet extractor exhaustively for 
20–24 h. The extracts were concentrated to dryness under reduced 
pressure and controlled temperature (40–50°C). The dried extracts 
obtained were used in this study.
Tube formation assay
Matrigel™ (BD Biosciences, Heidelberg, Germany) was thawed at 4°C 
overnight. 96-well plate was coated with 50-μl Matrigel™ per well and 
incubated at 37°C for 20 min for polymerization. Human umbilical vein 
endothelial cells (HUVECs) (2 × 105 cells/ml of endothelial growth 
medium) were seeded onto the Matrigel™ coated plate and treated with 
different concentration of extracts. After 18 h incubation, the endothelial 
tube-like structure, which was defined as endothelial tube formations 
that connected at both ends, is observed under the microscope (Leica 
DM IRB microscope) and scored [11].
Animal maintenance
All animals taken for the study were handled similarly and with 
due regard for their welfare. Care of animals complied with the 
regulations of Committee for the Purpose of Control and Supervision 
of Experiments on Animals, Government of India. The study design was 
reviewed and approved by the Institutional Animal Ethics Committee 
(protocol number-07/IAEC-01/CAN/2015). 68-week-old C57BL/6 
mice were taken from an in-house breeding facility of Orchid Chemicals 
and Pharmaceuticals Ltd., Chennai, India. Animals were maintained 
in individually ventilated cages, Allentown systems with a controlled 
environment, a temperature of 22±3°C, humidity of 50±20%, a light/
dark cycle of ~12 h, and minimum 50 fresh air changes per hour.
In vivo matrigel plug assay
Matrigel™ the gelatinous protein mixture was thawed on ice overnight 
at 4°C. Aliquots of 0.5 ml of Matrigel™ (containing VEGF 165 and 
heparin) [11] were injected subcutaneously into the sides of each 
mouse. 68-week-old male C57BL/6 mice were taken from in-house 
breeding. The dose of an individual animal was adjusted based on 
the body weight. All visible clinical signs were observed once a day 
throughout the experimental period. All the animals were checked 
daily for morbidity, mortality, and body weight. At the end of the study, 
animals were euthanized by CO2 to excise the Matrigel plugs from the 
animals. Matrigel plugs from the control and treatment groups were 
photographed and then fixed in 10% formalin <24 h, and histopathology 
studies were carried out.
Histopathology
Matrigel plugs were fixed at 10% buffered formalin and processed 
in automatic tissue processor (Citadel 2000, Thermo Shandon, UK) 
embedded with the help of automatic tissue embedded (Histocenter2, 
Thermo Shandon, USA) in paraffin. 3–5-µ sections were taken using 
microtome (Finesse-E, Thermo Shandon, UK) in positively charged 
frosted slides for Hematoxylin (Himedia, 51694) and Eosin (Himedia, 
81692) staining. The sections were examined using a light microscope 
(NIKON, ECLIPSE-E200, Japan). Scoring for the Matrigel sections for the 
microvessels is quantified based on Kwon et al. [10]. The submitted pre-
trimmed Matrigel plugs were routinely processed using alcohol, xylene, 
and embedded in paraffin wax. Apart from that, the plug sections were 
scored using Nikon eclipse 200 microscopes fitted with a calibrated 
1-mm reticle in the eyepiece. Based on the reticle length of 2.5 µ per 
division in ×400 magnification, the area of the same magnified field was 
calculated to be ~1.57 mm2 by the formula pi Xd where d=0.4995 µ. 
Several ×400 magnified fields were examined covering the entire plug 
section without allowing the fields to overlap and assess the area of 
entire plug section in mm2.
Statistical analysis
The values are expressed as mean±standard error of the mean. The 
graphs were generated using GraphPad Prism® (Version 4). Statistical 
analysis was performed by two-way ANOVA followed by Bonferroni 
post-test and one-way ANOVA followed by Dunnett’s post-test.
RESULTS
Tube formation assay
Hydroethanolic extract of A. heterophyllus prevented VEGF-
stimulated tube formation of HUVECs, in a dose-dependent manner 
(50 µg/kg–200 µg/kg; Fig. 1: AD). The extract at different doses 
exhibited the inhibition of tube formation of HUVECs. The VEGF-
dependent angiogenesis was found to be inhibited by the extract dose-
dependently. The complete inhibition of tube formation was observed at 
higher concentrations where most of the cells appeared as unorganized 
cell aggregates.
Tube formation assay in HUVECs was seeded onto the Matrigel™-coated 
plate; the cells were treated for 18 h with hydroethanolic extract; their 
endothelial tube-like structure images was captured; and an apoptotic 
score of various concentration of extract is as shown in Table 1.
An antiangiogenic activity of a hydroethanolic extract of 
A. heterophyllus
The in vitro antiangiogenic property of a hydroethanolic extract 
of A. heterophyllus was further studied in vivo in the Matrigel™ plug 
angiogenesis assay. The effect on neovascularization in responses 
to VEGF-A was evaluated by injecting Matrigel™ (with and without 
Table 1: Matrigel scoring system
Compound Concentration (µm/µg) Score
Control - 4
Curcumin 10 1




Apoptotic score for hydroethanolic extract at various concentration;  
curcumin-internal standard; control-untreated control
Fig. 1: The effect of Artocarpus heterophyllus in tube formation 
assay in human umbilical vein endothelial cells. (a) control, 
(b) extract 50 µg, (c) extract 100 µg, (d) extract 150 µg, (e) extract 
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supplements of VEGF-A and Heparin) subcutaneously into the 
flank regions of C57/BL6 mice. Animals were treated with different 
concentrations of the hydroethanolic extract of A. heterophyllus 
for 10 days. The onset of neovascularization within the Matrigel™ 
plug was evaluated by histology. The Matrigel™ plugs in the control 
group - VEGF-A added groups were visually bloodier which suggests 
an enhanced level of angiogenesis (Fig. 2). Hematoxylin and Eosin 
staining of the vasculature within the plugs has revealed more vessel-
like structures within the vehicle control VEGF-A supplemented 
group than the treated. Although the blood vessel formation was 
not significantly inhibited at lower doses, however, at higher 
concentrations, the blood vessel formation was significantly inhibited 
(p<0.01), demonstrating the in vivo antiangiogenic activity of the 
hydroethanolic extract in the Matrigel™ plug angiogenesis assay (Fig. 
3). There was observed >50% inhibition of blood vessels in mice 
treated with higher concentration (500 mg/kg p.o) of hydroethanolic 
extract compared with controls, suggesting the demonstrating the 
in vivo antiangiogenic activity of the hydroethanolic extract. Fig. 4 
describes the photographed images of Matrigel plug after treatment 
of extract at different concentrations.
DISCUSSION
CONCLUSION
Our current research emphasized on the use of the hydroethanolic 
extract of A. heterophyllus for its antiangiogenic potential through 
direct inhibition of endothelial cell as well as it was found to possess 
in vivo angiogenesis with less toxicity to mice. The angiogenic potential 
Fig. 3: The effect of the hydroethanolic extract of Artocarpus 
heterophyllus inhibited the new blood vessel formation
Fig. 4: The effect of Artocarpus heterophyllus in Matrigel at different concentration. (a) Vehicle control - matrigel+vascular endothelial 




Fig. 2: Histological representative slides of Matrigel plug-
inhibition of tube formation. (a) Vehicle control vascular 
endothelial growth factor, (b) extract 100 mg/kg p.o, (c) extract 




Cancer is a molecularly heterogeneous disease and the leading 
cause of death worldwide [12]. Despite many advance research has
 focused on cancer prevention, considerable attention has focused on
 medicinal plants as a major source of anticancer agents for a long time in 
the history of oncology treatment. There are more attempts being made 
to study the role of seeds, spices, and plant parts and their constituents in 
therapeutic  and  pharmacological  applications,  such  source  derived 
phytochemicals  have  an  enormous  potential  in  the  prevention  and 
treatment  of  cancer.  They  can  induce  apoptosis,  suppress 
proliferation of tumor cells, and inhibit invasion and angiogenesis
 [13,14]. The new pharmacological effects of A. heterophyllus have 
been confirmed by the proven inhibition of  angiogenesis both in vitro 
and in vivo  studies. In the present study, the evaluation of the arrest of 
endothelial  cells  and  angiogenesis  by  blocking  the  VEGF  signaling 
pathway.  We  further  demonstrated  the  antiangiogenic  potential  of 
hydroethanolic extract of A. heterophyllus inhibitors on various 
angiogenic  functions of  HUVECs,  the most  commonly used 
endothelial cell for in vitro  angiogenesis assays. Boerhaavia 
diffusa  extracts  support  strong  claims  of  antiangiogenic  ethnomedical 
properties by chicken chorioallantoic membrane (CAM) assay in vivo [15]
 The  chick  CAM  treated  with  methanolic  leaf  extract  and  methanolic 
flower extracts of Calotropis procera showed distorted vascularization 
revealing  potent  antiangiogenic  property  [16].  The  process  of 
angiogenesis  depends  on  the  increase  in  the  viability  and 
proliferation  of  endothelial  cells,  and  VEGF  is  a  major 
pro-angiogenic  factor  that  governs  angiogenesis,  in  both 
physiological and pathological settings. Secretion of VEGF by tumor cells 
in response to hypoxia is an important factor that drives tumor 
angiogenesis  [17].  Extract  of  Vigna  angularis  effectively  attenuated 
the phosphorylation of VEGFR2, Erk, and Akt in VEGF-treated HUVECs [18]. 
To  confirm  in  vivo  antiangiogenic  activity  of  hydroethanolic  extract, 
Matrigel plug assay was performed in mice orally administered
 by extracts. Angiogenesis is processed through the interaction of the
 VEGF  family  of  pro-angiogenic  cytokines  and  their  receptors.  The 
VEGF family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and 
placental  growth  factor  with  three  receptors  including  VEGFR-1 
(fms-like tyrosine kinase 1/Flt- 1), VEGFR-2 (flk-1/KDR), and VEGFR-3 
[19,20]. The ethanolic extract of Artemisia sieberi is strongly inhibited
 the angiogenesis in HUVECs and chick CAM models, by reducing the
 transcription  of  VEGFR-1,  VEGFR-2,  and  CD34  genes  in  a 
concentration-dependent  manner  [21].  From  the  current  study,  we 
report  that  A.  heterophyllus  significantly  suppressed  the  VEGF-induced 
angiogenesis. Such food-based therapeutic approach may be safer to use,
 and  more  number  of  animal  studies  and  clinical  trials  are  needed  to 
prove the usefulness of these agents.
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of A. heterophyllus might have been executed either by preventing 
signaling of angiogenic agents from epithelial cells or by induction 
of apoptosis, preventing promotional events in the tissues. However, 
further studies are needed to elucidate the exact mechanism underlying 
the antiangiogenic property of A. heterophyllus. The profound results 
might generate better clinical understanding and generate new 
therapeutic approaches.
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